These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1301 related articles for article (PubMed ID: 29874546)
21. Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD-L1-positive locally advanced or metastatic non-small-cell lung cancer: KEYNOTE-042 China Study. Wu YL; Zhang L; Fan Y; Zhou J; Zhang L; Zhou Q; Li W; Hu C; Chen G; Zhang X; Zhou C; Dang T; Sadowski S; Kush DA; Zhou Y; Li B; Mok T Int J Cancer; 2021 May; 148(9):2313-2320. PubMed ID: 33231285 [TBL] [Abstract][Full Text] [Related]
22. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC). Hsu PC; Jablons DM; Yang CT; You L Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387256 [TBL] [Abstract][Full Text] [Related]
23. Heterogeneity of EGFR-mutant clones and PD-L1 highly expressing clones affects treatment efficacy of EGFR-TKI and PD-1 inhibitor. Kunimasa K; Nakamura H; Sakai K; Kimura M; Inoue T; Tamiya M; Nishino K; Kumagai T; Nakatsuka S; Endo H; Inoue M; Nishio K; Imamura F Ann Oncol; 2018 Oct; 29(10):2145-2147. PubMed ID: 30099497 [No Abstract] [Full Text] [Related]
24. Pembrolizumab for the better treatment of EGFR-mutant T790M-negative advanced lung adenocarcinoma patients than dual treatment of pemetrexed plus platinum after tyrosine kinase inhibitor treatment failure. Lu Z; Ye M; Sun T; Wu S; Lin Z; Zhang X; Rao D; Zhang D; Ke Y; Chen Z Ann Palliat Med; 2022 Jun; 11(6):2100-2109. PubMed ID: 35817745 [TBL] [Abstract][Full Text] [Related]
25. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. Brahmer JR; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Zhang J; Lubiniecki GM; Deitz AC; Rangwala R; Reck M Lancet Oncol; 2017 Dec; 18(12):1600-1609. PubMed ID: 29129441 [TBL] [Abstract][Full Text] [Related]
26. Association between PD-L1 expression and driver gene mutations in non-small cell lung cancer patients: correlation with clinical data. Karatrasoglou EA; Chatziandreou I; Sakellariou S; Stamopoulos K; Kavantzas N; Lazaris AC; Korkolopoulou P; Saetta AA Virchows Arch; 2020 Aug; 477(2):207-217. PubMed ID: 31989260 [TBL] [Abstract][Full Text] [Related]
27. Differential Efficacy of Pembrolizumab According to Metastatic Sites in Patients With PD-L1 Strongly Positive (TPS ≥ 50%) NSCLC. Takeyasu Y; Yoshida T; Shibaki R; Matsumoto Y; Goto Y; Kanda S; Horinouchi H; Yamamoto N; Motoi N; Ohe Y Clin Lung Cancer; 2021 Mar; 22(2):127-133.e3. PubMed ID: 33183972 [TBL] [Abstract][Full Text] [Related]
28. Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With EGFR Mutation. Su S; Dong ZY; Xie Z; Yan LX; Li YF; Su J; Liu SY; Yin K; Chen RL; Huang SM; Chen ZH; Yang JJ; Tu HY; Zhou Q; Zhong WZ; Zhang XC; Wu YL J Thorac Oncol; 2018 Nov; 13(11):1668-1675. PubMed ID: 30056164 [TBL] [Abstract][Full Text] [Related]
29. First-line pembrolizumab for non-small cell lung cancer patients with PD-L1 ≥50% in a multicenter real-life cohort: The PEMBREIZH study. Amrane K; Geier M; Corre R; Léna H; Léveiller G; Gadby F; Lamy R; Bizec JL; Goarant E; Robinet G; Gouva S; Quere G; Abgral R; Schick U; Bernier C; Chouaid C; Descourt R Cancer Med; 2020 Apr; 9(7):2309-2316. PubMed ID: 32022459 [TBL] [Abstract][Full Text] [Related]
30. Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. Garon EB; Hellmann MD; Rizvi NA; Carcereny E; Leighl NB; Ahn MJ; Eder JP; Balmanoukian AS; Aggarwal C; Horn L; Patnaik A; Gubens M; Ramalingam SS; Felip E; Goldman JW; Scalzo C; Jensen E; Kush DA; Hui R J Clin Oncol; 2019 Oct; 37(28):2518-2527. PubMed ID: 31154919 [TBL] [Abstract][Full Text] [Related]
31. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer. Ng TL; Liu Y; Dimou A; Patil T; Aisner DL; Dong Z; Jiang T; Su C; Wu C; Ren S; Zhou C; Camidge DR Cancer; 2019 Apr; 125(7):1038-1049. PubMed ID: 30548240 [TBL] [Abstract][Full Text] [Related]
32. EGFR Mutation and TKI Treatment Promote Secretion of Small Extracellular Vesicle PD-L1 and Contribute to Immunosuppression in NSCLC. Liu HM; Yu ZL; Xia HF; Zhang LZ; Fu QY; Wang Y; Gong HY; Chen G Biomolecules; 2024 Jul; 14(7):. PubMed ID: 39062533 [TBL] [Abstract][Full Text] [Related]
33. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Herbst RS; Baas P; Kim DW; Felip E; Pérez-Gracia JL; Han JY; Molina J; Kim JH; Arvis CD; Ahn MJ; Majem M; Fidler MJ; de Castro G; Garrido M; Lubiniecki GM; Shentu Y; Im E; Dolled-Filhart M; Garon EB Lancet; 2016 Apr; 387(10027):1540-1550. PubMed ID: 26712084 [TBL] [Abstract][Full Text] [Related]
34. Response with pembrolizumab in a patient with EGFR mutated non-small cell lung cancer harbouring insertion mutations in V834L and L858R. Hadfield MJ; Turshudzhyan A; Shalaby K; Reddy A J Oncol Pharm Pract; 2022 Apr; 28(3):717-721. PubMed ID: 34783273 [TBL] [Abstract][Full Text] [Related]
35. [A Real-world Study on the Expression Characteristics of PD-L1 in Patients with Advanced EGFR Positive NSCLC and Its Relationship with the Therapeutic Efficacy of EGFR-TKIs]. Chen R; Gao X; Xu F; Zhang S; Ma L; Hu B Zhongguo Fei Ai Za Zhi; 2023 Mar; 26(3):217-227. PubMed ID: 37035884 [TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with Stage IV non-small cell lung cancer. Besse B; Garrido P; Cortot AB; Johnson M; Murakami H; Gazzah A; Gil M; Bennouna J Lung Cancer; 2020 Apr; 142():63-69. PubMed ID: 32114283 [TBL] [Abstract][Full Text] [Related]
37. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. Reck M; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Leiby MA; Lubiniecki GM; Shentu Y; Rangwala R; Brahmer JR; N Engl J Med; 2016 Nov; 375(19):1823-1833. PubMed ID: 27718847 [TBL] [Abstract][Full Text] [Related]
38. Increased EGFR Phosphorylation Correlates with Higher Programmed Death Ligand-1 Expression: Analysis of TKI-Resistant Lung Cancer Cell Lines. Suda K; Rozeboom L; Furugaki K; Yu H; Melnick MAC; Ellison K; Rivard CJ; Politi K; Mitsudomi T; Hirsch FR Biomed Res Int; 2017; 2017():7694202. PubMed ID: 29119113 [TBL] [Abstract][Full Text] [Related]
39. A Randomized Phase III Study of Pembrolizumab Versus Pembrolizumab-Carboplatin-Pemetrexed for Locally Advanced or Metastatic Nonsquamous Non-small-cell Lung Cancer with PD-L1 50% or more (LAPLACE-50): Study Protocol. Kogure Y; Hashimoto H; Oki M Clin Lung Cancer; 2021 Nov; 22(6):e921-e924. PubMed ID: 34053861 [TBL] [Abstract][Full Text] [Related]
40. Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation. Yang JC; Gadgeel SM; Sequist LV; Wu CL; Papadimitrakopoulou VA; Su WC; Fiore J; Saraf S; Raftopoulos H; Patnaik A J Thorac Oncol; 2019 Mar; 14(3):553-559. PubMed ID: 30529597 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]